Amy Rich
Family · Sewickley, PANPI 1134773195
Payments from drug & device makers
Across 215 payments — averaging $52.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$9K
- Novo Nordisk$830
- Lilly USA, LLC$461
- Tandem Diabetes Care, Inc.$400
- Insulet Corporation$154
- Amgen$140
- plus $791 from 19 others
What the payments were for
- Speaking & faculty fees$7,35065%
- Travel & lodging$3683%
- Food & beverage$3,62132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 58 | $8,562 |
| Novo Nordisk | 69 | $830 |
| Lilly USA, LLC | 24 | $461 |
| Tandem Diabetes Care, Inc. | 11 | $400 |
| Insulet Corporation | 6 | $154 |
| Amgen | 8 | $140 |
| Xeris Pharmaceuticals, Inc. | 7 | $124 |
| Sanofi-aventis U.S. LLC | 3 | $109 |
| Bayer | 5 | $82 |
| Abbott | 3 | $57 |
| IBSA Pharma Inc. | 3 | $55 |
| Amarin Pharma, Inc. | 3 | $51 |
| BD | 2 | $39 |
| BETA Bionics, Inc. | 1 | $35 |
| Antares Pharma, Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $30 |
| Medtronic | 1 | $27 |
| Mannkind Corporation | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $19 |
| AbbVie | 1 | $19 |
| Novartis | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$6,318
- DEXCOM G7 GSS (161)$1,470
- RYBELSUS$119
How this compares
$11,339 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $60,094 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $9,841 |
| SynthroidLevothyroxine Sodium | 11 | $536 |
| Levothyroxine Sodium | 34 | $476 |
| Rosuvastatin Calcium | 17 | $366 |
| Metformin Hcl | 14 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $830 | $60,09447 claims |
| AbbVieSynthroid | $19 | $53611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Sewickley
- Stacey CoyleSewickley$15K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.